The work presents a novel method for the design of vaccines, which consists on the conjugation of a dendrimeric structure to a transporter protein. This result becomes itself an owner technology that allows obtaining vaccinal candidates with high immunogenicity and crossed reactivity, and with flexibility for the formulations of several epitopes.

The results are endorsed by 4 publications, 3 of which are very important in this subject, also giving birth to a patent, presented in Cuba and in 20 countries. In the pattern of answer against the V3 region of human immunodeficiency virus, it was demonstrated how this answer depends on the coupling agent, being the conditions that achieve an excellent answer against the virus without a strong answer against the coupling agent.

The developed technology allows reducing the immunogen doses, which has great practical importance, and also allows increasing the crossed reactivity, which is something completely new, not previously described and potentially very important for the development of vaccines against pathogens with a high variability. Besides the possibilities that it creates for the design of new vaccinal candidates for HIV, the developed technology has a general application in other systems, and, in fact, it is being used in projects of the Center for Biotechnology and Genetic Engineering and (CIGB) vaccines against meningococcus B and dengue.